CORRESPONDENCE
Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis Neuralgic amyotrophy (also known as Parsonage-Turner syndrome, idiopathic brachial neuritis, or brachial plexopathy) is characterized by severe, sudden-onset upper limb pain followed by weakness within a few hours or days, not responsive to analgesics [1, 2] . The pathogenesis is unknown, but the idiopathic form is believed to be immunemediated. It is difficult to recognize because often the pain, paresis, and sensory symptoms are not all in the same nerve territory distribution, and so there is an average delay of 3 to 9 months before diagnosis is made [1, 2] . Although the brachial plexus can be affected in a patchy manner, upper and middle trunk distribution is most common. Neuralgic amyotrophy has been mainly described following surgery [3] , viral infection, or immunosuppression [4] . A hereditary form also exists associated with a point mutation or duplication of the SEPT9 gene, and is much rarer. It is treated conservatively with analgesics, physical therapy, and occasionally steroids in the acute period [1] . Parrish et al. [5] reported three cases of neuralgic amyotrophy in patients with multiple myeloma following high-dose melphalan and autologous stem cell transplantation (HDM/SCT), but there has never been a reported case after treatment of immunoglobulin light chain (AL) amyloidosis following HDM/SCT. Here we report two cases of neuralgic amyotrophy following HDM/SCT for AL amyloidosis. These cases were prospectively identified from a population of 42 patients with AL amyloidosis who underwent HDM/SCT at Boston Medical Center between January 2014 and June 2017.
Case 1
The first case was a 68-year-old woman with AL amyloidosis and renal involvement with an associated lambda clonal plasma cell dyscrasia who had been diagnosed 3 months prior to undergoing HDM/SCT (melphalan dose 200 mg/m 2 ), without induction chemotherapy. She had no history of peripheral neuropathy or other neurologic disorder. Neutrophil engraftment was prompt and occurred on day + 9 after HDM/SCT. On day + 12, she developed acute onset severe bilateral shoulder pain associated with weakness, left greater than right. The pain and weakness were so extensive that she needed assistance with activities of daily living. She had no preceding viral illness. Neurologic evaluation at the time was notable for weakness in left shoulder abduction (4/5), and left elbow flexion and extension (4/5). Sensation to pinprick was decreased on the dorsum of the left hand. Deep tendon reflexes were 2+ in the biceps, brachioradialis, and triceps. These deficits were consistent with C5-8 motor and sensory dysfunction. She had magnetic resonance imaging (MRI) of the cervical spine and brachial plexus that showed edema within the supraspinatus and infraspinatus musculature, suggestive of neuralgic amyotrophy. Electromyography/nerve conduction studies (EMG/NCS) of the upper extremities revealed scattered nerve anomalies, left greater than right, indicative of a motor sensory neuropathy, axonal in nature, consistent with bilateral neuralgic amyotrophy. Doppler ultrasound of the upper extremities was negative for deep venous thrombosis. Lyme disease and West Nile virus infections were both ruled out. She began treatment with physical therapy and her symptoms resolved within 2 years following HDM/SCT.
Case 2
The second case was a 58-year-old woman with Waldenström's macroglobulinemia (WM) and associated AL amyloidosis with renal involvement and an underlying lambda clonal plasma cell dyscrasia who was initially diagnosed with WM 8 years prior to her diagnosis of AL amyloidosis. She received eight cycles of rituximab, cyclophosphamide, vincristine, and prednisone for treatment of WM, and then four cycles of rituximab, bortezomib, and dexamethasone after diagnosis of AL amyloidosis. She then underwent HDM/ SCT (melphalan dose 200 mg/m 2 ). She had a history of lower extremity sensory peripheral neuropathy secondary to her prior treatments with vincristine and bortezomib, but had no other neurologic symptoms. Neutrophil engraftment occurred on day + 10 after HDM/SCT. On day + 13, she developed acute onset left shoulder pain with simultaneous weakness. Pain was severe enough to wake her up at night. She had no viral symptoms. She denied any tingling or numbness. Exam demonstrated mild atrophy of the left deltoid muscle and weakness of left shoulder abduction (3/5) and adduction (4/ 5), elbow flexion (4/5) and extension (2/5), wrist extension (4 +/5) and flexion (5−/5). The right upper extremity was also weak including right shoulder abduction (4+/5) and adduction (5−/5), elbow flexion (4+/5) and extension (4−/5), wrist extension and flexion (5/5). Sensory exam was normal and reflexes were 3 + in the biceps, brachioradialis, and triceps bilaterally. MRI of the cervical spine demonstrated mild multilevel degenerative changes. MRI of the left brachial plexus demonstrated T1 hyperintensity of the upper, middle, and lower trunks of the left brachial plexus without associated enhancement or mass. (Fig. 1) There was also associated mild T2 hyperintensity and mild enhancement of the left subscapularis, supraspinatus, and infraspinatus. These findings were consistent with neuralgic amyotrophy. Her symptoms completely resolved by 1 year post-SCT with physical therapy.
These two cases of neuralgic amyotrophy following HDM/SCT are, to our knowledge, the first reported cases in association with AL amyloidosis. Previously, a handful of neuralgic amyotrophy cases with similar time courses have been described after both autologous and allogeneic SCT in association with multiple myeloma, non-Hodgkin's lymphoma, myelodysplastic syndrome, diffuse large B-cell lymphoma, and multiple sclerosis [5] [6] [7] . An autoimmune process has previously been postulated, especially given the known phenomenon of immune dysregulation following SCT during the period of immune reconstitution [8] . Toxicity from induction chemotherapy seems unlikely, because prior case reports of neuralgic amyotrophy following hematopoietic SCT used different chemotherapy regimens [5] . Direct trauma was not a contributing factor in either case; both patients had an internal jugular tunneled venous catheter on the right side, but their shoulder pain was worse on the left side.
We conclude that neuralgic amyotrophy is an uncommon, but potential early complication of HDM/SCT for AL amyloidosis that should be considered in patients with new sudden onset shoulder pain and weakness that is either unilateral or asymmetrically involving the other extremity. The latter was seen in both of our cases. Areas of hypesthesia in the upper extremity are also common, like in our first case [2] . And, similar to our second case, asymmetric atrophy of the upper extremity muscles, such as the deltoid and brachialis muscles, has been seen in idiopathic cases of neuralgic amyotrophy [2] . Diagnosis is made with a combination of physical examination, MRI, and EMG/NCS, and it is often misdiagnosed due to the heterogeneity of presentation. Anecdotal evidence shows that steroids can reduce the duration of pain in the acute period, and physical therapy may be beneficial to patients with this self-limited disorder [1] . Recovery is expected within 2-3 years in the majority of cases [2] .
